Gastrointestinal therapies and pharmaceutical innovations by Phathom Pharmaceuticals
Phathom Pharmaceuticals scheduled for 2:40 PM fireside chat at major healthcare event
Phathom Pharmaceuticals will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference today. The session, set for 2:40 PM EDT, offers investors and industry ...
Phathom Pharmaceuticals unveils commercial strategy momentum at Jefferies conference
Phathom Pharmaceuticals has made available the replay of its recent fireside chat at the Jefferies Global Healthcare Conference. President and CEO Steve Basta and Chief Financial and Business ...
Phathom Pharmaceuticals honors Tachi Yamada legacy in GI medicine
Phathom Pharmaceuticals today commemorated the birthday of its late Chairman and Founder, Dr. Tadataka “Tachi” Yamada, known widely as the Godfather of GI. The company emphasized Dr. Yamada ...
Phathom Pharmaceuticals to engage investors at multiple conferences in May and June
Phathom Pharmaceuticals announced plans to participate in several investor conferences throughout May and June. The company invited investors to tune in for the latest updates via virtual and ...
Phathom Pharmaceuticals calls for greater EoE research to address daily life impact in U.S.
Eosinophilic esophagitis (EoE) impacts approximately one in 2,000 people in the U.S., posing significant challenges to daily life. Phathom Pharmaceuticals is leveraging #EoEDay to advocate for ...
Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care
Phathom Pharmaceuticals CEO Steve Basta has outlined key takeaways from a dynamic DDW2026, signaling efforts to accelerate progress in serving the gastrointestinal (GI) community. The company is ...
Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago
Phathom Pharmaceuticals announced its upcoming participation at Digestive Disease Week (DDW2026) in Chicago. The company invited attendees to visit booth 2511 to meet its team and referenced an ...
Phathom Pharmaceuticals to present VOQUEZNA clinical data at DDW2026 event
Phathom Pharmaceuticals will host a live product theater presentation on Monday, May 4 at 12:00 pm CDT during DDW2026, focusing on VOQUEZNA (vonoprazan). The company will present updated data on ...
Phathom Pharmaceuticals brings senior marketing leader to ThinkDHC patient engagement event
Phathom Pharmaceuticals announced that Nancy Phelan, Senior Vice President of Marketing and Analytics, will participate in an upcoming ThinkDHC webinar focused on the future of point-of-care ...
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment
Phathom Pharmaceuticals is sponsoring the 3rd Great GI Debates Conference, scheduled to be held from February 6-8 in Fort Lauderdale, Florida. The event will provide an opportunity for attendees ...
Phathom Pharmaceuticals: VOQUEZNA hits 1 million U.S. prescriptions milestone
Phathom Pharmaceuticals has announced that its medication, VOQUEZNA, has surpassed the milestone of 1 million prescriptions dispensed in the United States since its launch. This achievement marks ...
Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk
Phathom Pharmaceuticals has unveiled new research findings indicating that the use of GLP-1s in individuals with Type 2 Diabetes is associated with higher rates of gastroesophageal reflux disease ...
